📣 VC round data is live. Check it out!

GIMV Valuation Multiples

Discover GIMV's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like FIBRA Macquarie, L1 Long Short Fund, HBM Healthcare Investments, Antin Infrastructure Partners and more.

GIMV Overview

About GIMV

GIMV NV is a Belgium-based company active in investing in companies having growth potential, with the objective of supporting its growth into market leaders. The company invests with a focus on four platforms, which are also its segments: Consumer, Health and Care, Smart Industries, and Sustainable Cities. Its geographical segments include Belgium, Netherlands, Germany, France, and the Rest of Europe and Other countries.


Founded

1980

HQ

Belgium

Employees

94

Website

gimv.com

Financials (FY)

Revenue: $393M
Net Income: $255M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

GIMV Financials

GIMV reported last fiscal year revenue of $393M.

In the same fiscal year, GIMV generated $255M in net income.


GIMV P&L

In the most recent fiscal year, GIMV reported revenue of $393M and net income of $255M.

GIMV is profitable as of last fiscal year, with net margin of 65%.

See analyst estimates for GIMV
Last FY202320242025202620272028
Revenue$393M$246M$378M$393M
Net Profit$255M$172M$254M$255M
Net Margin65%70%67%65%

Financial data powered by Morningstar, Inc.

GIMV Stock Performance

GIMV has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


GIMV's stock price is $53.58.

GIMV share price decreased by 5.4% in the last 30 days, and increased by 11.1% in the last year.

GIMV has an EPS (earnings per share) of $6.94.

See more trading valuation data for GIMV
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-5.3%-5.4%0.5%11.1%$6.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

GIMV Valuation Multiples

GIMV trades at 6.1x EV/Revenue multiple.

See NTM and 2027E valuation multiples for GIMV

GIMV Financial Valuation Multiples

As of June 3, 2026, GIMV has market cap of $2B and EV of $2B.

GIMV has a P/E ratio of 7.7x.

Last FY202320242025202620272028
EV/Revenue6.1x9.7x6.3x6.1x
P/E7.7x11.4x7.7x7.7x
EV/FCF(40.4x)(46.0x)(41.6x)(40.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified GIMV Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

GIMV Margins & Growth Rates

In the most recent fiscal year, GIMV reported net margin of 65%.

See estimated margins and future growth rates for GIMV

GIMV Margins

Last FY20242025202720282029
Net Margin65%67%65%
FCF Margin(15%)(15%)(15%)

GIMV Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth54%4%
Net Profit Growth48%0%
FCF Growth11%3%

Data powered by FactSet, Inc. and Morningstar, Inc.

GIMV Operational KPIs

GIMV's revenue per employee in the last FY averaged $4.2M, while opex per employee averaged $1.5M for the same period.

Access forward-looking KPIs for GIMV
Last FY202320242025202620272028
Revenue per Employee$4.2M---
Opex per Employee$1.5M---
S&M Expenses to Revenue-6%4%-
G&A Expenses to Revenue8%9%8%8%
Opex to Revenue35%29%33%35%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
FIBRA Macquarie10.5x10.4x13.8x13.6x
L1 Long Short Fund9.7x---
HBM Healthcare Investments6.1x20.7x--
Antin Infrastructure Partners4.8x4.8x8.3x8.8x
L1 Group18.0x5.6x77.1x7.8x
AFP ProVida4.8x-7.4x-
Tri-Continental7.5x---
Patria Investments5.1x5.0x10.1x9.3x

This data is available for Pro users. Sign up to see all GIMV competitors and their valuation data.

Start Free Trial

Acquisitions by GIMV

GIMV has acquired 29 companies to date.

Last acquisition by GIMV was on July 22nd 2025. GIMV acquired Hemink Groep for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by GIMV

Hemink Groep
Alpine
The Spice Factory
Tibbloc
Description
Hemink Groep is a Dutch property service provider headquartered in Deventer delivering maintenance, renovation, and complete outfitting for residential and commercial buildings. The company handles electrical installations, HVAC systems, plumbing, and painting projects across the Netherlands. With a workforce specialized in multi-trade execution, Hemink Groep manages turnkey projects from initial assessment to final handover. Serving housing associations, property developers, and corporate clients, the firm emphasizes sustainable building practices and compliance with Dutch building codes.
Alpine Hearing Protection is a Netherlands-based manufacturer of custom-fit earplugs for musicians, motorsport enthusiasts, and industrial workers. Its product line includes models like MusicSafe, MotoSafe, and WorkSafe, sold through retailers in Europe and beyond.
The Spice Factory is a U.S.-based manufacturer and wholesaler of bulk herbs, spices, seasonings, and custom blends for foodservice, retail, and industrial clients. Operating from Ohio, it sources organic and conventional products including pepper, garlic, paprika, and spice mixes, offering private labeling, grinding, and packaging services compliant with FDA standards.
Tibbloc is a France-based provider of rental services for temporary heating, cooling, air treatment, steam generation, and compressed air equipment for construction and industrial projects.
HQ CountryNetherlandsNetherlandsBelgiumFrance
HQ City
Enschede
Utrecht
Braine-l'Alleud
Nantes
Deal Date22 Jul 202524 Jun 202520 Feb 20254 Dec 2024
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all GIMV acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by GIMV

GIMV has invested in 39 companies to date.

Latest investment by GIMV was on January 20th 2026. GIMV invested in Exciva in their $60M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by GIMV

Exciva
Kinaset Therapeutics
spineart
Kivu Bioscience
Description
Exciva is a Heidelberg-based provider of targeted drug rescue programs for pharmaceutical research and development. The company develops symptomatic and disease-modifying treatments by repurposing approved drugs for new indications, including therapies, cures, prophylactics, supplements, and formulations. These efforts support healthcare organizations in rescuing and reusing existing drugs through specialized methods of production and application.
Kinaset Therapeutics is a Melbourne-headquartered clinical-stage company developing inhaled therapeutics for respiratory diseases. Its lead asset KIN-301 targets idiopathic pulmonary fibrosis with Phase 1 data showing safety in 50 patients. The pipeline includes candidates for COPD and asthma, licensed from Monash University research.
spineart designs and distributes sterile-packed implants with barcoded traceability and compact instrument sets from its Swiss operations. The portfolio covers minimally invasive surgery, motion preservation, fusion, biologics, and fracture treatments validated clinically for spine surgeons in Europe, Asia, and the Americas.
Kivu Bioscience is a biopharmaceutical company developing antibody-drug conjugates for oncology and immunology. Headquartered in Basel, Switzerland, it engineers site-specific ADCs with proprietary linkers and payloads for improved therapeutic indices. Kivu advances candidates like KV-001 targeting solid tumors through preclinical stages, leveraging platforms from former Roche scientists for scalable manufacturing.
HQ CountryGermanyUnited StatesSwitzerlandUnited States
HQ City
Heidelberg
Boston, MA
Geneva
San Francisco, CA
Deal Date20 Jan 202610 Jan 202626 Sep 202528 Oct 2024
RoundSeries BSeries BUndisclosed stageSeries A
Raised$60M$103M$31M$92M
InvestorsAndera Partners; Carma Fund; EQT; Fountain Healthcare Partners; GIMV; LBBW VC; LifeArc Ventures; Modi Ventures5AM Ventures; Atlas Venture; EQT; Forge Life Science Partners; GIMV; Pictet Alternative Advisors; RA Capital Management; Schroders Capital; Sixty Degree Capital; Vivo Capital; Willett Advisors LLCEGS Beteiligungen; GIMVBioGeneration Ventures; BOM; GIMV; HealthCap; M Ventures; Novo Holdings; Red Tree Venture Capital
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all GIMV investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About GIMV

When was GIMV founded?GIMV was founded in 1980.
Where is GIMV headquartered?GIMV is headquartered in Belgium.
How many employees does GIMV have?As of today, GIMV has over 94 employees.
Who is the CEO of GIMV?GIMV's CEO is Koen Dejonckheere.
Is GIMV publicly listed?Yes, GIMV is a public company listed on Euronext Brussels.
What is the stock symbol of GIMV?GIMV trades under GIMB ticker.
When did GIMV go public?GIMV went public in 1997.
Who are competitors of GIMV?GIMV main competitors include FIBRA Macquarie, L1 Long Short Fund, HBM Healthcare Investments, Antin Infrastructure Partners, L1 Group, AFP ProVida, Tri-Continental, Patria Investments, BWP Gr, AG Anadolu Grubu Holding.
What is the current market cap of GIMV?GIMV's current market cap is $2B.
What is the current revenue of GIMV?GIMV's last fiscal year revenue is $393M.
What is the current EV/Revenue multiple of GIMV?Current revenue multiple of GIMV is 6.1x.
Is GIMV profitable?No, GIMV is not profitable.
How many companies GIMV has acquired to date?As of June 2026, GIMV has acquired 29 companies.
What was the largest acquisition by GIMV?$259M acquisition of Smart Battery Solutions on 28th May 2019 was the largest M&A GIMV has done to date.
In how many companies GIMV has invested to date?As of June 2026, GIMV has invested in 39 companies.
What was the last GIMV investment?On 20th January 2026 GIMV invested in Exciva, participating in a $60M Series B round, alongside Andera Partners, Carma Fund, EQT, Fountain Healthcare Partners, LBBW VC, LifeArc Ventures, and Modi Ventures.
In what companies GIMV invested in?GIMV invested in Kinaset Therapeutics, JenaValve Technology, Kivu Bioscience, Precirix, Mediar Therapeutics, Complement Therapeutics, ImmunOs Therapeutics, Covagen, Exciva, Anjarium Biosciences, Almaviva Santé, ImCheck Therapeutics, Lampiris, FIRE1, Breath Therapeutics, SynOx Therapeutics, iSTAR Medical, Endosense, Biotalys, Biom'Up, and 19 other companies.

See public comps similar to GIMV

Lists including GIMV

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial